NEW YORK (GenomeWeb News) – Proteome Sciences, ProQinase, and the NMI Natural and Medical Sciences Institute at the University of Tübingen have started a three-year project to establish new workflows for developing and evaluating inhibitors targeting tumor protein kinases, Proteome Sciences said today.
The aim of the BioTag project, which is funded by the German Federal Ministry of Research and NMI, is to develop biomarker tests that can support kinase target validation studies, establish proof of concept for candidate kinase inhibitors, and to monitor treatment response in pre-clinical and early clinical studies.
The project will develop new molecular strategies for target expression and biomarker profiling and develop biomarkers that will be used to translate early drug candidates into human clinical trials.
"The need for more objective measures of drug safety and efficacy during pre-clinical and clinical development is widely recognized and the adoption of biomarkers for such purposes is supported by the pharmaceutical industry and regulators," Proteome Sciences CEO Christopher Pearce said in a statement.